Immune Response to Third Dose of SARS-CoV-2 Vaccine in a Cohort of Cancer Patients on Active Treatment
Latest Information Update: 06 Oct 2023
At a glance
- Drugs SARS-COV-2 vaccine-inactivated-Sinovac-Biotech (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- 01 Feb 2022 Planned End Date changed from 1 Jan 2022 to 1 Jun 2022.
- 01 Feb 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Mar 2022.
- 19 Nov 2021 New trial record